Bangkok: T.MAN Pharmaceutical PCL, a leading manufacturer and distributor of pharmaceuticals and health products, is set to commence trading on the Stock Exchange of Thailand (SET) on 22 October under the ticker ‘TMAN’ with a market capitalization of 6,520.06 million baht at its initial public offering price.
According to Thai News Agency, Ms. Rungtip Charoenvisutthiwong, Assistant Manager, Issuer Group 2, Stock Exchange of Thailand, announced the inclusion of T.MAN Pharmaceutical PCL in the SET listing. The company will be categorized under the Consumer Products industry group, specifically in the Personal Care and Medical Supplies category. The introduction of TMAN on the SET marks a significant step for the company, which offers an extensive range of over 200 proprietary brands and also undertakes contract manufacturing.
TMAN’s product lineup is diversified into modern drugs, herbal products, dietary supplements, cosmetics, and other health-related products. Some of the company’s prominent brands include
Propoliz, Iyara, Myda, IBUMAN, Polar, and Vita-C, all of which are well-received in the market.
The company has set the IPO share price at 16.30 baht, offering 102 million common shares, which includes 71.43 million new shares and 30.57 million existing shares held by TKW Capital Limited. The offering was made available between October 10-11 and 15, 2024, and managed by Kasikorn Securities Public Company Limited, which also served as the financial advisor.
Mr. Prapol Thanachotephan, Chief Executive Officer of T.Man Pharmaceutical PCL, expressed the company’s commitment to innovation and the creation of effective health products aimed at enhancing quality of life. Leveraging over 50 years of experience and ongoing research and development, TMAN aims to meet consumer needs comprehensively. The funds raised from the IPO are primarily intended for the expansion and enhancement of production capabilities to foster future growth.
Post-IPO, the Thanachotephan family will remain the major shareholders, holding 74.
5% of the company. TMAN has also declared a dividend policy that ensures a minimum payout of 30% of net profits, adhering to legal reserves and other internal regulatory requirements, aligning with the interests of the company and its shareholders.